Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1094568
Max Phase: Preclinical
Molecular Formula: C12H17F2N5O9P2S
Molecular Weight: 507.31
Molecule Type: Small molecule
Associated Items:
ID: ALA1094568
Max Phase: Preclinical
Molecular Formula: C12H17F2N5O9P2S
Molecular Weight: 507.31
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CSc1nc(N)c2ncn([C@@H]3O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)O)[C@@H](O)[C@H]3O)c2n1
Standard InChI: InChI=1S/C12H17F2N5O9P2S/c1-31-11-17-8(15)5-9(18-11)19(3-16-5)10-7(21)6(20)4(28-10)2-27-30(25,26)12(13,14)29(22,23)24/h3-4,6-7,10,20-21H,2H2,1H3,(H,25,26)(H2,15,17,18)(H2,22,23,24)/t4-,6-,7-,10-/m1/s1
Standard InChI Key: PLBBQVYTRYDROT-KQYNXXCUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 507.31 | Molecular Weight (Monoisotopic): 507.0190 | AlogP: -0.32 | #Rotatable Bonds: 7 |
Polar Surface Area: 223.37 | Molecular Species: ACID | HBA: 12 | HBD: 6 |
#RO5 Violations: 3 | HBA (Lipinski): 14 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: -0.27 | CX Basic pKa: 5.16 | CX LogP: -3.17 | CX LogD: -5.72 |
Aromatic Rings: 2 | Heavy Atoms: 31 | QED Weighted: 0.16 | Np Likeness Score: 0.31 |
1. Eliahu S, Martín-Gil A, Perez de Lara MJ, Pintor J, Camden J, Weisman GA, Lecka J, Sévigny J, Fischer B.. (2010) 2-MeS-beta,gamma-CCl2-ATP is a potent agent for reducing intraocular pressure., 53 (8): [PMID:20337495] [10.1021/jm100030u] |
2. Lecka J, Ben-David G, Simhaev L, Eliahu S, Oscar J, Luyindula P, Pelletier J, Fischer B, Senderowitz H, Sévigny J.. (2013) Nonhydrolyzable ATP analogues as selective inhibitors of human NPP1: a combined computational/experimental study., 56 (21): [PMID:24083941] [10.1021/jm400918s] |
Source(1):